procedur
develop
gener
recombin
singl
chain
fv
scfv
antibodi
fragment
react
extracellular
domain
human
cell
surfac
antigen
aminopeptidas
n
intact
cell
membran
fraction
prepar
stabli
transfect
murin
nih
cell
line
use
immun
balb
c
mice
intent
would
major
immunogen
molecul
recogn
immun
system
spleen
rna
immun
mice
serv
gener
combinatori
scfv
phage
display
librari
librari
adsorb
nontransfect
nih
insect
cell
elimin
nonrelev
binder
supernat
use
pan
either
insect
cell
human
leukemiaderiv
cell
line
therefor
key
concept
procedur
present
sole
human
antigen
murin
nih
cell
screen
strategi
major
common
antigen
materi
use
immun
pan
two
differ
phage
isol
solubl
scfv
express
e
coli
purifi
two
scfv
differ
four
amino
acid
posit
v
region
high
affin
h
determin
surfac
plasmon
reson
k
respect
effici
recogn
intact
cell
therefor
procedur
allow
product
high
affin
scfv
react
desir
antigen
nativ
conform
without
requir
extens
purif
antigen
use
prepar
scfv
conformationsensit
cellsurfac
antigen
function
membranebound
metalloproteinas
catalyz
remov
ntermin
infant
leukemia
associ
transloc
amino
acid
polypeptid
small
peptid
affect
mllgene
mizutani
et
al
hooper
chromosom
poor
prognosi
new
express
epitheli
cell
liver
kidney
therapeut
approach
leukemia
intestin
placenta
brain
spleen
need
behm
et
al
heerema
et
al
varieti
hematopoiet
cell
recent
role
immunotherapeut
approach
target
individu
metastasi
degrad
exantigen
tumor
cell
suffer
past
tracellular
matrix
compon
tumor
cell
fact
antigen
also
report
saiki
et
al
fujii
et
al
present
normal
cell
contrast
mixedaddit
identifi
receptor
lineag
antigen
spectrum
preferenti
found
tumorhom
peptid
vasculatur
tumor
tumor
cell
therefor
offer
novel
possiand
appear
play
role
aberr
angiobl
specif
target
tumor
cell
genesi
tumor
tissu
therefor
longrang
object
research
contribut
propos
use
target
deliveri
drug
develop
immunotherapeut
apto
tumor
aim
inhibit
angiogenesi
pasproach
leukem
blast
chromosom
qualini
et
al
furthermor
receptor
transloc
mll
gene
cytomegaloviru
cmv
soderberg
et
al
purpos
cdna
code
antibodi
giugni
et
al
certain
coronavirus
deantibodi
fragment
reactiv
sever
lma
et
yeager
et
al
futur
compon
antigen
mix
lineag
spectrum
antivir
strategi
direct
virus
may
need
also
benefit
includ
target
lar
immedi
purpos
present
studi
sson
et
al
gener
recombin
singl
chain
fv
fragment
hematopoiet
system
express
scfv
bind
human
nativ
conformapredominantli
myelomonocyt
cell
shapiro
et
tion
intact
human
leukem
blast
knowlal
shipp
look
olsen
et
al
edg
report
scfv
reactiv
antigen
present
earli
hematopoiet
intact
cell
publish
although
number
progenitor
includ
progenitor
band
tof
antihuman
hybridoma
antibodi
lymphoid
lineag
express
progress
report
goyert
standard
procedur
reduc
increas
matur
cell
gener
scfv
consist
bacteri
antigen
detect
matur
lymphocyt
express
antigen
follow
biochem
peripher
blood
spleen
tonsil
spit
et
purif
use
purifi
antigen
al
often
upregul
malign
immun
mice
howev
heavili
cell
particularli
blast
acut
chronic
glycosyl
look
et
al
authent
bcell
leukemia
all
cll
includ
infant
glycosyl
achiev
bacteri
express
prob
cell
leukemia
makrynikola
et
al
therefor
mice
immun
bacteri
exprob
all
frequent
express
press
antigen
may
produc
antibodi
react
lymphoid
marker
recombin
protein
myeloid
marker
stong
et
al
antigen
nativ
conform
human
cell
greil
et
al
express
myeloid
chowdhuri
et
al
hul
et
al
marker
prob
cell
background
unusu
altern
strategi
avoid
use
bacteri
highli
characterist
particular
leukemia
express
would
involv
prepar
therefor
special
term
includ
biphenotyp
cell
surfac
membran
posit
human
express
mixedlineag
phenotyp
cell
leukemia
cell
coin
design
properti
stong
et
al
greil
et
al
disth
mix
lineag
phenotyp
provid
uniqu
advantag
approach
immun
opportun
direct
novel
immunotherapeut
apmic
like
produc
excess
antibodi
proach
prob
all
often
human
cell
surfac
antigen
antirefractori
form
treatment
particular
bodi
may
low
abund
scfv
would
therefor
difficult
contain
code
sequenc
fc
portion
isol
combinatori
phage
librari
prepar
human
heavi
chain
peipp
unpublish
immun
mice
without
specif
modidata
result
chimer
protein
nficat
procedur
ad
maxim
termin
portion
consist
extracellular
doprob
isol
scfv
desir
main
fc
domain
human
antigen
avoid
problem
novel
procedur
cterminu
design
design
purpos
maxim
yield
scfv
antibodi
cultur
eukaryot
cell
avoid
product
antibodi
human
cell
surfac
antigen
inde
procedur
nih
murin
fibroblast
human
produc
recombin
scfv
human
kidney
cell
cultur
dmemglutamaxi
high
frequenc
advantag
new
procedur
medium
life
technolog
karlsruh
germani
requir
extens
biochem
supplement
fetal
calf
serum
fc
purif
antigen
result
penicillin
streptomycin
life
technolog
partial
total
loss
nativ
conform
concentr
u
ml
mg
ml
respecanticip
procedur
applic
tive
leukemiaderiv
sem
cell
greil
et
germani
transfect
perform
follow
digest
spei
ecorv
insert
manufactur
protocol
select
medium
conwa
ligat
speiecorv
digest
tain
mg
ml
exchang
everi
invitrogen
groningen
netherland
result
day
week
select
singl
cell
construct
stabl
transfect
subclon
isol
clone
analyz
cell
ecorvnoti
fragment
surfac
express
fluorescentactiv
cdna
ligat
invitrogen
cell
sort
fac
cell
seed
result
express
solubl
mm
plate
cell
well
ndeilinear
cdna
fragment
lack
transmembran
vector
mg
bsteii
linear
intracellular
domain
amplifi
pcr
vector
carri
zeocin
resist
primer
use
amplif
gene
mg
cotransfect
use
transfast
gat
atc
aga
aga
aca
reagent
promega
mannheim
germani
aga
acg
cca
ggc
week
continu
select
mg
ml
ggc
cgc
tcg
tgt
ttt
ctg
tga
acc
pcr
zeocin
mix
cell
popul
examin
amplim
ligat
vector
psectagcfc
fac
surfac
express
popula
pcr
amplif
immunower
suspend
lysi
buffer
consist
mm
globulin
variabl
region
cdna
clone
nahco
ph
mm
mgcl
mm
phagemid
vector
perform
delock
proteinas
inhibitor
roth
karlsruh
gerscrib
krebber
et
al
initi
commani
incub
ice
min
binatori
scfv
librari
propag
sbcell
disrupt
dounc
homogen
medium
glucos
mg
ml
chloramphenicol
lysat
clear
centrifug
sucros
vigor
shake
densiti
ad
final
concentr
tenml
cultur
reach
od
ml
aliquot
overlay
rotor
tube
beckcultur
infect
helper
phage
man
munich
germani
ml
stratagen
cultur
incub
sucros
carbon
buffer
mm
nahco
ph
anoth
min
without
shake
ml
second
layer
ml
sucros
third
sbmedium
ad
isopropyl
bdthiogalaclay
ml
sucros
ad
gradient
topyranosid
iptg
suppli
final
concentrifug
perform
h
centrat
mm
cultur
incub
rotor
membran
fraction
anoth
h
vigor
shake
lect
dilut
volum
phosphat
buffer
rev
min
kanamycin
ad
mg
salin
pb
sediment
h
ml
final
cultur
incub
previous
describ
eylar
hagopian
overnight
phage
precipit
polymembran
resuspend
ml
pb
ethylen
glycol
peg
nacl
fraction
contain
identifi
resuspend
ml
pb
elisa
balb
c
mice
charl
river
sulzfeld
germani
pan
phage
display
librari
intact
cell
maintain
accord
european
guidewa
carri
use
two
differ
approach
line
protect
laboratori
anim
apboth
case
phage
display
librari
first
proxim
mg
gradientpurifi
membran
adsorb
nontransfect
cell
protein
combin
titermax
gold
adblock
nonfat
dri
milk
pb
nmpb
juvant
sigma
deisenhofen
germani
inject
min
first
approach
ml
phage
subcutan
day
day
mice
display
librari
resuspend
nmpb
boost
mg
membran
protein
incub
h
rt
block
nonfin
inject
mg
membran
protein
transfect
nih
cell
preadsorb
librari
follow
day
four
day
later
mice
use
posit
select
sem
sacrif
spleen
recov
steril
leukem
cell
purpos
sem
cell
condit
serum
test
differ
block
nmpb
incub
timepoint
presenc
antibodi
preadsorb
scfv
librari
h
rt
slow
fac
analysi
use
cell
tranagit
cell
wash
time
nmpb
twice
pb
bound
phage
nitrilotriacet
acid
ninta
magnet
agaros
elut
ml
mm
hcl
min
bead
qiagen
neutral
ml
trishcl
ph
cell
pellet
supernat
use
flow
cytometr
analysi
infect
ml
exponenti
grow
e
coli
cell
cultur
ml
medium
confor
monitor
scfv
bind
intact
cell
tain
glucos
mg
ml
chloramphenicol
cell
wash
pb
contain
ad
cell
incub
h
bsa
mm
naazid
pba
cell
vigor
shake
rev
min
cell
incub
either
ml
bacteri
periplasm
superinfect
helper
phage
seventi
ml
extract
ml
purifi
scfv
mgml
h
medium
ad
iptg
ice
periplasm
extract
cell
produc
concentr
adjust
mm
two
hour
nonrelev
scfv
fragment
serv
isotyp
conaft
infect
kanamycin
ad
final
trol
cell
wash
pba
concentr
mg
ml
cultur
incub
ml
mg
ml
pentahi
allow
grow
overnight
follow
antibodi
qiagen
min
ice
unbound
day
phage
prepar
describ
antibodi
remov
wash
pba
second
approach
nontransfect
insect
cell
ml
pe
conjug
antiwer
use
preadsorb
phage
display
librari
bodi
bectondickinson
heidelberg
germani
posit
select
perform
ad
cell
pellet
cell
cell
pan
procedur
describ
incub
min
ice
final
wash
individu
phage
clonal
purifi
fac
analysi
perform
facscalibur
sequenc
analysi
insert
perform
use
use
cellquest
softwar
bectondickinson
ten
dideoxynucleotid
sequenc
sambrook
et
al
thousand
event
collect
sampl
appli
biosystem
autom
dna
analys
whole
cell
perform
use
sequenc
abi
prism
genet
analyz
perkin
appropri
scatter
gate
exclud
cellular
debri
elmer
ueberlingen
germani
aggreg
monitor
surfac
express
transfect
cell
line
cell
incub
min
ice
ml
bacteri
express
purif
antibodi
clone
dako
diagnostica
solubl
scfv
fragment
gmbh
hamburg
germani
concentr
mg
ml
mous
serv
isotyp
control
solubl
express
antibodi
fragment
cell
wash
pba
ml
pe
plasmid
propag
e
coli
conjug
antibodi
dr
g
winter
mrc
cambridg
uk
overnight
ad
final
wash
cell
analyz
cultur
dilut
medium
supdescrib
plement
glucos
mg
ml
chloramphenicol
extinct
nm
od
express
solubl
cultur
grown
od
mammalian
cell
express
induc
addit
iptg
final
concentr
mm
cell
transient
transfect
lower
temperatur
h
plasmid
contain
cdna
code
bacteria
collect
centrifug
periplasus
reagent
roch
mannheim
germic
extract
prepar
use
establish
protomani
h
medium
contain
fc
col
kipriyanov
dialyz
extens
reduc
igg
content
life
technolog
buffer
contain
mm
nah
po
ph
ad
begin
h
transfect
mm
nacl
mm
imidazol
medium
exchang
everi
h
cultur
purif
tag
scfv
fragment
supernat
contain
secret
colachiev
affin
chromatographi
nickellect
day
day
purif
perform
protein
agaros
column
biorad
tion
singl
cell
clone
line
nih
germani
describ
elsewher
harlow
clone
express
elev
level
lane
commerci
antigen
surfac
judg
fac
bodi
clone
use
identifi
stain
commerci
antibodi
elisa
fig
mean
fluoresc
intens
nih
clone
stain
sdspage
western
blot
analysi
bodi
time
greater
nontransfect
nih
cell
cell
stain
isotyp
sdspage
carri
accord
laemmli
control
antibodi
fig
although
absolut
gel
stain
coomassi
brilliant
surfac
densiti
express
number
blue
western
blot
towbin
et
al
molecul
per
cell
determin
disperform
secondari
antibodi
coupl
tribut
cell
respect
fluoreshorseradish
peroxidas
hrp
dianova
hamburg
cenc
intens
compar
distribut
germani
detect
use
ecl
reagent
amerobtain
leukemiaderiv
sem
cell
line
sham
freiburg
germani
scfv
detect
data
shown
therefor
clone
exth
pentahi
antibodi
qiagen
press
suffici
surfac
densiti
detect
use
hrp
conjug
antihumanfc
use
prepar
membran
fraction
antibodi
sigma
immun
mice
surfac
plasmon
reson
prepar
enrich
plasma
determin
bind
constant
membran
nih
cell
immun
balb
c
mice
immobil
sensor
chip
standard
amin
coupl
biacor
ab
freiburg
procedur
outlin
fig
generatgermani
amount
deposit
ing
nih
murin
line
express
monitor
surfac
plasmon
reson
coupl
membran
fraction
prepar
gentl
conwa
continu
amount
deposit
corresdit
avoid
denatur
antigen
pond
reson
unit
ru
bind
enrich
plasma
membran
fraction
use
analys
purifi
scfv
fragment
immun
mice
procedur
dialyz
run
buffer
intend
avoid
product
antibodi
mm
hepe
ph
mm
edta
mm
nacl
human
plasma
membran
protein
surfact
scfv
fluid
immun
balb
c
mice
exphas
allow
interact
immobil
pect
toler
membran
rt
flow
rate
ml
min
tigen
nih
cell
possibl
excepvari
concentr
scfv
analyz
tion
alloantigen
membran
prepar
chip
regener
bind
nih
clone
gentl
hypoton
constant
calcul
use
biaevalu
disrupt
subsequ
densiti
centrifug
softwar
kazemi
et
al
langmuir
sucros
gradient
sever
membran
fraction
model
biacor
ab
collect
gradient
fraction
identifi
elisa
data
shown
peak
fraction
use
immun
result
balb
c
mice
averag
prepar
mg
plasma
membran
protein
gener
nih
cell
line
cover
cell
estim
enrichexpress
ment
plasma
membran
protein
day
three
boost
immun
two
nih
cell
line
stabli
express
mice
develop
high
titer
circul
antihuman
establish
antibodi
judg
sampl
aliquot
peripher
blood
variou
time
performcombin
pan
combin
librari
ing
flowcytometr
assay
cell
tain
independ
clone
transient
transfect
cell
isol
phage
prepar
combinatori
phage
librari
differenti
pan
display
scfv
antibodi
fragment
piii
tail
fiber
protein
pan
perform
employ
two
differ
variant
protocol
variant
librari
combinatori
scfv
cdna
librari
produc
preadsorb
nontransfect
nih
total
spleen
rna
immun
mice
cell
supernat
pan
intact
accord
publish
procedur
krebber
et
al
sem
leukemia
cell
variant
mg
total
spleen
rna
comth
librari
preadsorb
nontransfect
binatori
librari
independ
insect
cell
supernat
pan
chloramphenicolresist
clone
obtain
bewith
cell
therefor
fore
amplif
mous
k
light
chain
cdna
insect
cell
transfect
cdna
construct
amplifi
includ
librari
l
code
mixtur
stabli
transfect
light
chain
omit
repres
clone
use
pan
procedur
small
proport
mous
antibodi
six
mixtur
express
suffici
stabil
separ
librari
produc
character
judg
flow
cytometri
obviat
need
phage
determin
enrich
factor
calcul
rel
first
round
pan
three
round
reactiv
phage
enrich
pan
sem
cell
pan
posit
cell
tabl
individu
isol
phage
clonal
purifi
specif
bind
evalu
cellular
elisa
result
individu
isol
phage
third
round
pan
specif
react
nih
cell
stabli
express
show
bind
nontransfect
nih
cell
data
shown
character
cdna
insert
phage
reveal
two
differ
scfv
clone
isol
multipl
time
independ
use
variant
pan
protocol
ident
light
chain
variabl
region
v
differ
four
amino
acid
posil
tion
heavi
chain
variabl
region
v
two
h
chang
locat
complementaritydetermin
region
two
fig
flow
diagram
improv
procedur
isol
found
framework
fig
anti
scfv
key
step
procedur
outlin
three
sequenti
round
pan
employ
isol
scfv
anti
singl
cell
subclon
mean
fluoresc
infor
purpos
largescal
express
tensiti
cell
stain
antibodi
recombin
antibodi
fragment
cdna
code
fold
greater
intens
scfv
subclon
express
cell
stain
isotypecontrol
antibodi
vector
e
coli
strain
chosen
nontransfect
cell
fig
high
level
express
scfv
intact
recomth
phage
specif
bound
cell
binant
scfv
secret
periplasm
comwer
elut
mm
hydrochlor
acid
hcl
partment
visual
western
blot
immedi
neutral
titer
elut
antibodi
reactiv
hexahistidin
tag
fig
factor
enrich
calcul
set
input
elut
ratio
first
round
comput
ratio
measur
subsequ
round
multipl
first
round
ratio
normal
first
round
histidin
tag
ctermin
extens
allow
affin
purif
magnet
ninta
bead
protocol
prepar
result
typic
yield
describ
periplasm
compart
purif
onestep
purif
procedur
result
scfv
nta
bead
reduc
onestep
procedur
essenti
free
contamin
detect
stain
coomassi
blue
fig
lane
human
antibodi
fig
data
shown
scfv
indic
two
scfv
react
two
scfv
isol
react
nativ
state
nativ
conform
fail
react
extract
cell
western
blot
data
shown
therefor
determin
molecular
bind
constant
scfv
necessari
gener
antigen
nativ
conform
pure
state
achiev
object
antigen
fuse
fcdomain
human
antibodi
sinc
procedur
known
gener
solubl
antigen
nativ
conform
peipp
unpublish
data
procedur
chimer
molecul
secret
mammalian
cell
receiv
posttransl
modif
eg
glycosyl
characterist
mammalian
cell
purpos
secret
sequenc
code
leader
peptid
murin
immunoglobulin
k
light
chain
fuse
code
sequenc
extracellular
domain
fig
purpos
high
level
express
cell
transient
transfect
construct
solubl
human
produc
high
quantiti
sever
day
transfect
chimer
protein
collect
cultur
supernat
purifi
affin
chromatographi
protein
agaros
column
use
procedur
typic
mg
recombin
protein
recov
l
cultur
supernat
chimer
molecul
react
western
blot
antibodi
fcportion
fig
contamin
breakdown
product
visibl
stain
coomassi
blue
fig
materi
react
elisa
commerci
antibodi
well
two
isol
scfv
data
shown
thu
integr
antigen
epitop
chimer
molecul
resembl
intact
cell
solubl
chimer
ligand
de
posit
biacor
sensor
chip
fig
scfv
also
inject
ly
coupl
standard
procedur
sequenti
round
blank
inactiv
surfac
signal
load
perform
total
amount
subtract
signal
obtain
coupl
correspond
rel
unit
ru
surfac
remov
contribut
potenti
unthen
scfv
allow
flow
chip
specif
bind
result
affin
fluid
phase
associ
dissoci
reaction
monitor
surfac
plasmon
suggest
nanc
procedur
allow
reliabl
measurelow
affin
tabl
therefor
sequenc
ment
associ
k
dissoci
rate
differ
v
region
scfv
may
h
constant
k
affin
k
determin
result
measur
differ
affin
nud
scfv
antibodi
quotient
k
k
meric
valu
affin
nanomolar
procedur
perform
sever
differ
rang
typic
high
affin
concentr
scfv
fluid
phase
antibodi
result
secondari
immun
separ
chip
anti
griffith
et
al
thu
novel
procedur
report
effici
captur
scfv
high
affin
immun
mice
main
result
studi
establish
novel
procedur
gener
recombin
scfv
reactiv
preselect
antigen
surfac
human
leukocyt
procedur
deliv
scfv
react
nativ
state
surfac
intact
cell
high
affin
without
requir
extens
purif
antigen
principl
compon
distinct
featur
procedur
follow
establish
stabli
transfect
nih
mous
insect
cell
line
express
high
level
cell
surfac
b
purif
membran
nih
mous
cell
express
gentl
extract
maintain
antigen
nativ
state
c
immun
mice
membran
contain
sole
human
antigen
preadsorpt
phage
display
librari
nontransfect
nih
cell
allow
remov
antibodi
alloantigen
well
nonspecif
protein
e
pan
preadsorb
librari
human
relat
method
produc
scfv
plasmon
reson
solubl
chimer
protein
deposit
ligand
biacor
sensor
chip
purifi
cell
surfac
antigen
previous
report
solubl
scfv
appli
chip
portolano
et
al
cai
garen
increas
concentr
allow
bind
bind
siegel
et
al
hul
et
al
winthrop
monitor
surfac
plasmon
reson
use
biacor
xe
et
al
ridgway
et
al
top
et
al
system
b
associ
dissoci
profil
scfv
major
case
librari
respect
number
right
margin
concentr
purifi
solubl
scfv
use
curv
data
pan
subtract
tumorand
nonar
repres
two
separ
experi
tumor
cell
line
result
scfv
analyz
without
prior
knowledg
ident
without
specif
featur
procedur
design
augment
effici
isol
antibodi
tabl
predetermin
specif
antigen
case
measur
associ
dissoci
rate
constant
report
scfv
preselect
affin
scfv
surfac
plasmon
specif
cell
surfac
antigen
isol
reson
pan
intact
cell
portolano
et
al
scfv
hoogenboom
et
al
key
featur
membran
fragment
purifi
transfect
murin
cell
line
membran
prepar
procedur
mice
immun
specif
nih
cell
inject
antigen
given
multipl
boost
recipi
mice
reason
human
secondari
possibl
even
tertiari
antigen
would
major
immunogen
immun
respons
well
underway
strategi
molecul
recogn
immun
system
increas
likelihood
affin
matur
second
import
point
screen
strategi
antibodi
vivo
subsequ
isol
high
major
common
antigen
beaffin
antibodi
furthermor
two
tween
materi
use
immun
differ
scfv
react
specif
cell
use
pan
allow
stringent
obtain
screen
librari
posit
select
intact
cell
best
clone
thu
strategi
describ
allow
us
knowledg
method
employ
similar
combinato
isol
high
affin
scfv
antigen
tion
step
previous
report
choic
compar
small
librari
proit
interest
contrast
advantag
cedur
use
prepar
scfv
disadvantag
procedur
previous
conformationsensit
cell
surfac
report
one
frequent
employ
method
antigen
clone
cdna
avail
pan
complex
nonimmun
naiv
synthet
procedur
design
gener
librari
griffith
et
al
vaughan
et
al
procedur
isol
novel
scfv
larg
knappik
et
al
advantag
provarieti
previous
unrecogn
cell
surfac
ancedur
one
univers
librari
use
tigen
exist
procedur
involv
subtract
screen
scfv
react
mani
differ
anwhol
cellpan
without
laborintens
retigen
nissim
et
al
synthet
librari
finement
ad
may
suffici
superior
necessarili
repres
naiv
repertoir
purpos
addit
scfv
isol
often
also
contain
high
affin
scfv
genear
murin
scfv
known
disadvantag
ration
librari
includ
hypermut
use
human
clinic
applic
although
region
librari
expand
disadvantag
reliev
chimerizto
consider
complex
librari
contain
ing
human
murin
scfv
may
still
differ
scfv
report
prefer
major
clinic
applic
vaughan
et
al
knappik
et
al
one
gener
human
scfv
begin
final
disadvantag
approach
librari
wish
detract
major
advantag
spite
hypermut
region
larg
combinatori
synthet
naiv
human
isol
anim
undergo
secondari
scfvlibrari
clearli
major
advantag
tertiari
immun
respons
specif
antigen
one
librari
human
scfv
mani
differ
although
high
affin
scfv
isol
antigen
isol
without
need
prior
use
approach
probabl
find
scfv
immun
major
gener
applic
specif
antigen
reduc
entail
exist
procedur
may
equal
superior
need
screen
larg
librari
differ
procedur
report
strength
clone
perelson
anoth
disadvantag
novel
procedur
specif
lie
gener
isol
specif
binder
defin
antigen
recombin
scfv
conform
sensit
cell
surfac
may
compromis
use
nonantigen
cdna
immun
synthet
librari
avail
recombin
scfv
report
nonimmun
antibodi
librari
contain
previous
obtain
recogn
antigen
binder
domin
epitop
noronha
et
al
nativ
state
intact
cell
case
hoogenboom
et
al
binder
domin
advantag
procedur
avoid
need
epitop
may
preferenti
amplifi
extens
biochem
purif
screen
decreas
probabl
isol
antigen
may
destroy
conformationsensith
desir
binder
specif
predetermin
antiv
epitop
epitop
may
exist
tigen
especi
screen
perform
use
antigen
present
nativ
conform
complex
antigen
whole
cell
cell
surfac
may
disappear
purifi
away
nearest
neighbor
membran
comact
agent
myeloid
leukemia
cell
ponent
narrow
segment
applic
xu
scheinberg
clear
procedur
report
present
signific
progress
scfv
murin
origin
repres
problem
human
demonstr
exampl
clinic
applic
may
still
clinic
scfv
previous
isol
recogus
demonstr
antibodi
human
nize
antigen
nativ
state
recent
approv
human
two
scfv
report
react
therapeut
agent
deriv
antigen
nativ
state
live
leukemia
cell
murin
monoclon
antibodi
perspect
affin
high
comparison
pubthes
scfv
correspond
cdna
may
lish
valu
griffith
et
al
antibodi
becom
valuabl
design
novel
therapeut
affin
nanomolar
rang
higher
high
strategi
leukemia
cell
affin
antibodi
vaughan
et
al
howev
caution
must
exert
compar
number
obtain
previous
publish
figur
acknowledg
sinc
differ
measur
procedur
util
case
solubl
scfv
use
work
support
research
grant
monoval
associ
dissoci
rate
deutsch
forschungsgemeinschaft
dfg
sfb
constant
measur
surfac
plasmon
grant
wilhelm
nanc
method
one
two
bind
sander
foundat
ghf
sjz
thank
prof
partner
immobil
solid
phase
gramatzki
provid
cem
cell
line
prof
freeli
mobil
fluid
phase
pluckthun
scfv
vector
dr
l
shapiro
immobil
partner
differ
kinet
human
cdna
clone
dr
g
winter
paramet
compar
reaction
coli
j
dorri
birkmann
dr
r
interact
partner
remain
fluid
phase
nieba
slani
acknowledg
valuabl
discuss
et
al
furthermor
mani
publish
affin
th
lang
administr
assist
constant
obtain
measur
procedur
antibodi
ligand
fluid
phase
therefor
numer
affin
valu
report
strictli
compar
previous
refer
publish
valu
intend
repres
absolut
valu
must
consid
approxibehm
fg
raimondi
sc
frestedt
jl
liu
q
crist
wm
mate
valu
proviso
indic
down
jr
rivera
gk
kersey
jh
pui
ch
scfv
high
affin
isol
rearrang
mll
gene
confer
poor
prognosi
childhood
acut
lymphoblast
leukemia
regardless
presentprocedur
ing
age
blood
antibodi
isol
may
cai
x
garen
antimelanoma
antibodi
becom
use
purpos
similar
monomelanoma
patient
immun
genet
modifi
auclon
antibodi
previtolog
tumor
cell
select
specif
antibodi
ousli
describ
other
purpos
includ
singlechain
fv
fusion
phage
librari
proc
natl
acad
sci
usa
human
celland
tissuetyp
goyert
